BioLineRX Ltd. Share Price TEL AVIV STOCK EXCHANGE
Equities
IL0011015182
Biotechnology & Medical Research
Sales 2024 * | 14.36M 5.47B 1.15B | Sales 2025 * | 27.77M 10.57B 2.22B | Capitalization | 52.63M 20.04B 4.21B |
---|---|---|---|---|---|
Net income 2024 * | -47M -17.89B -3.76B | Net income 2025 * | -36M -13.71B -2.88B | EV / Sales 2024 * | 3.66 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.9 x |
P/E ratio 2024 * |
-2.19
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.64% |
Latest transcript on BioLineRX Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 62 | 23/05/09 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 31/12/08 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 31/08/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 23/02/14 |
Avraham Molcho
BRD | Director/Board Member | 66 | 31/12/09 |
Aharon Schwartz
CHM | Chairman | 80 | 31/12/03 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |